<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 378 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page377.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=378">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 378 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 378</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=378"><img src="../thumb/378.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Biologicals / Enzymes - 26 / 27                                                2020-04 / 341
       (S2) SOL FOR INJ. 29/30.1/0091.  VAZIGAM IM, NBI [P/S]     Indications: Simultan.act.immunisat.against typhoid fev.& hepatit.A
       822442-019: 1x sngl.dos.pre-fill.syringe, R278,89  Human varicella-zoster immunoglobulin deriv.from pooled human   virus infects. in subj.16 yrs & old.
       Dosage: Vaccin.of childr.und.2 yrs.depends on dis. expos.risk.  plasma with high titre of antibodies to varicella-zoster virus, test.&   (S4) INJ, [P/S] 41/30.1/0025
       Adults & childr: Sngl.dos.of 0,5 ml by deep SC/IM inj.at least   found non-react.to HBsAg & antibodies to HCV, HIV-1 & HIV-2 viruses.  717194-001: 1x 2,5 ml prefill.dual chamb.syr., R549,72
       2 wks.prior to potent.expos. Revaccin. every 3 yrs.if still at risk.  Indications: Prophylax.of varicella in high risk pts. who have   Dosage: Recomm.dos: 1 ml of mix.vacc. Prim. vaccinat: 1 sngl.dos.
       Contraindications: Life-threaten.react.aft.prev. admin.of Typhin   had expos.  admin.at least 14 days prior to typhoid & hepatit.A expos.risk. Booster
       Vi/vacc.contain.same subst., safety in pregn. not est., not known   (S4) IM INJ. T/30.2/749. 100 IU/ml.  inj.of inact. hepatit.A vacc.to be giv.betw.6-36 mnths. aft.prim. vaccin.
       if excret.in breast milk, intravasc.admin.  793078-008: 1x2 ml amp, R758,23  Revaccinat.against typhoid fev.to be carried out with sngl.dos.of purif.
       Side effects: Loc.reacts., fev., headache, asthma, malaise, fatig.,   Dosage: IMI admin Warm to body temp.bef.use.  Vi polysaccharide typhoid vacc.with interv.of not more than 3 yrs in
       arthralg., myalg., GI disturbs., allerg. reacts.incl.ser.sickn/anaphylax.  Recomm.dose: &gt;15 IU/kg BM within 96 hrs. of expos.  subj.remain.at risk for typhoid fev. A booster dos. of hepatit.A may
       Special precautions: Postpone vaccin.in case of ac. infect.illn./  Up to 5 yrs: 2 ml. 6-10 yrs: 4 ml. 11-14 yrs: 5 ml. 15 yrs.& older: 6 ml.  be giv.if appropr.in which case VIVAXIM may be used. Combin.vacc.
       fev., protect.not conferr.against paratyphoid fev./illn.caus.by non-  Contraindications: Immune adults/childr., clinic. varicella/ shin-  may be giv.as booster in subj.who receiv.an inactiv.hepatit.A vacc.
       invas. Salmonellae., formaldehyde hypersens.as traces thereof   gles treatm., disseminat.zoster prophylax., weigh risk-benefit ratio   6-36 mnths earlier/inactive.hepatit.A vacc.& purif.Vi polysaccharide
       pres., immunosuppress.treatm./ immunodefic. reduc.immune re-  pts.with IgA defic. hist./sev.anaphylact.reacts.to plasma prod., IV   typhoid vacc.or combin. vacc.
       sponse theref. postpone vaccinat.to end of treatm., vaccinat.pts.   admin., bleed.disords., safety in pregn.not est.  Contraindications: Not recomm.in pregn., intravasc. inj., hypers-
       with chron.immunodefic.even if antibody response limit., may ad-  Side effects: Loc./anaphylact./skin reacts., headache, fev., chills,   ens.to resid.compon.
       min.at same time as other vacc. using diff.sites, childr.und.2 yrs.  flush., lightheadedn., backache, naus., IgA sensitisat., imp.effic.of   Side effects: Headache, dizzin., GI disturbs.incl. abdom.pain., pru-
       may show sub-optim. respons.but as typhoid rare in this age group   live attenuat. vir.vaccines.  rit., rash, urticar., myalg., arthralg., loc.reacts.incl.inj.site nodule,
       base vaccinat.decis.on expos.risk, poss. febrile react.if admin.at   Special precautions: Do not admin.more than 96 hrs. aft.expos.,   asthen., malaise, pyrex., anaphylact.reacts.incl.shock, ser.sickn.,
       same time as other meds. contain. endotoxin, keep adrenaline   as infect.dis.transmiss.cannot be tot. excl.consid.vaccinat.where ap-  asthma, incr.transamin.
       avail.in case of anaphylact. reacts., thrombocytopen., bleed. disords.  propr., admin. in.div. dos.at diff.sites if large vol. (&gt;2 ml for childr./ &gt;5   Special precautions: Delay in case of febr.illn., cons.benef./risk
                                     ml for adults) reqd., do not mix with oth. prods., if simultan.vaccinat.  in pregn., lactat., thrombocytopen. /bleed.disord., review medic.hist.
       VARILRIX, GSK [P/S]           necess. immunoglobul. & vacc. should be admin.at diff.sites to avoid   bef.admin./prev. sev.reacts.hist., have appropr.medic.treatm.avail. in
       Live attentuat.varicella-zoster virus vaccine.  interf. with act.antibody respon.  event of anaphylact.reacts., hypersens.to neomycin/ antibiot.in same
       Indications: Act.immunisat. of healthy infts.from 9 mnths./childr.&   class, if subj.in incubat. period at time of immunisat.eff.is not known,
       adolesc./suscept high-risk pts (incl. ac.leukaem./pts.und.immuno-  VECTIBIX, Amgen [P/S]  not for infect.caus.by other live pathogens incl. hepatit.B/C/E virus,
       suppress. treatm./ plann.organ transplant./ chron.dis. predisp.to   Panitumumab  admin.other concom. inact. vaccin.at diff.inj.sites, immunogenic.re-
       sev.varicella) & suscept.close contacts against varicella.  Indications: Monother.for wild type KRAS metastat. colorect. Ca   duc. by immunosuppress.treatm./immunodefic., vaccin. recomm.for
       (S4) INJ, 32/30.1/0468. 2 000 pfu/0,5 ml  (mCRC) where oxaliplatin/ fluoropyrimidine & irinotecan contain.   HIV-infect./chron.immunodefic.indiv., no protect.against Salmonella
       892939-001: 1x 3 ml vial, R407,59  chemother.regim.have fail.  paratyphi A/B or non-typhoid. Salmonellae.
       Dosage: Admin.SC only. 0,5 ml reconstitut.vacc.= 1 immunising   (S4) SOL.FOR INFUS., 44/30.1/0110. 20 mg/ml
       dose. Admin.entire contents immed. aft.reconstit.as a sngl.dos.   714612-001: 100 mg, 1x5 ml vial, R5 258,73  ZOSTAVAX, MSD [P/S]
       Allow swab area to dry bef.admin.  For further details refer to manufacturers product lit.  Live attentuat.varicella-zoster virus vaccine.
       Childr.9 mnths.-12 yrs: 2 dos. 13 yrs.& old: 2 dos. Admin. 2   nd  VERORAB, Sanofi Aventis [P/S]  Indications: Prev./reduc.sever.of herpes zoster/post-herpet.neu-
              st
       dos.6 wks.aft. 1  dos. Interv.should und. no circumst. be &lt; 4 wks.   Rabies vir.using Wistar rabies PM/WI 38 1503-3M strain obt.from   ralg./ac.& chron. zoster-assoc.pain, immunisat.of indiv.50 yrs & old.
       Add.dos.may be reqd. in high risk pts.  cult.on Vero cell lines, inactiv.with beta-propiolactone.  (S4) INJ, 44/30.1/0058. 19 400 pfu/0,65 ml
       Contraindications: Sev.humor./ cell. immunodefic. incl.subj.with   Indications: Rabies pre-expos.prophylax.in indiv. at incr.expos., ra-  717466-001: 1 vial & dil., R1 652,71
       prim./acquir. immunodefic. states with total lymphocyte count   bies prev.aft.confirm/suspect. expos.  Dosage: Admin.SC as sngl.dos. Admin.immed. aft.reconstit.
              3
       &lt; 1 200 per mm /present.other evid.of lack of cell. immune com-  (S4) INJ. V/30.1/220.  Contraindications: Neomycin hypersens.hist., prim./acquir.immu-
       pet./receiv.immunosuppress.ther.incl. high dos.corticoster, neo-  1 immunis.dos.≥ 2,5 IU/0,5 ml reconstit.dos.  nidefic.states, immunosuppress. ther.incl.high-dos.corticoster., act.
                                                                  untreat.TB, pregn., intravasc. inj., safety & effic.not est.in adults who
       mycin hypersens., pregn., other concom.live attenuat.vacc.admin.  814970-001: 1 vial+syringe with dil., R448,41
       in high risk pts., intraderm./IV admin.  Dosage: Strict IMI admin.direct.into deltoid musc. Adapt accord.to   are known to be HIV infect.with/ without immunosuppress.evid., mix.
                                                                  with any other meds.in same syr., concom.Pneumovax 23, concom.
       Side effects: Very comm: Pain, redn., Comm: Rash, swell.at   circumst.& pts.rabies immune status.
       inj. site, fev.(oral/axillary temp. &gt; 37,5 °C/ rect. temp. &gt; 38,0 °C).   Pre-expos.prophylax: Prim.vaccinat: 3 inj.of 0,5 ml on days D0,   antivir.meds.known to be effect.against VZV not eval.
                                                                  Side effects: Headache, loc.reacts., pyrex., hypersens.incl.anaphy-
       Uncomm: URTI, pharyngit., lymphadenopathy, irritabil., head-  D7 & D28 follow.by a booster 1 yr.aft.1st inj. D28 inj.may be admin.on
       ache, somnol., cough, rhinit., N&V, varicella-like rash, prurit.,   D21. Boosters: thereaft.one inj.every 5 yrs.aft.the last inj.  lact.react., swell., pain, prurit.
                                                                  Special precautions: Avoid pregn.for 3 mnths. post immunisat.,
       arthralg., myalg., fev.(oral/axillary temp. &gt; 39,0°C/ rect. temp.&gt;   Post-expos.prophylax: Flush wound with soap/ detergent immed.
       39,5°C), fatig., malaise. Rare: Conjunctivit., abdom.pain, diarrh.,   follow.bite. then admin.curat. vaccinat.und.med.supervis. Non-im-  lactat., appropr.emerg.prov.in place in case of anaphylax., cons.vac-
                                                                  cin.deferr.if fev.great.than 38,5 C, not recomm.in paed.use, vaccin.
       urticar. Unknown: Herpes zoster, thrombocytopen., hypersens.,   munis.subj: Adults & childr: 5x0,5 ml inj.on days 0, 3, 7, 14, 28.   poss.not protect all indiv., react.hist.to prev.VZV-cont.vacc., other
       anaphylact.reacts., encephalit, cerebrovasc. accid., cerebellitis/-  Complement.passive immunisat.on day 0 with human rabies immu-  vaccinat.poss.at diff. sites at the same time, transmiss.risk, not a
       cerebellitis like sympts. (incl.trans.gait disturb.& trans.atax.), con-  noglobulin at 20 IU/kg bm. infiltrat.as much as poss.around wound   treatm. for zost./post-herpet.neuralg., may be admin.concom.with
       vuls., vasculit. (incl. Henoch Schonlein purpura & Kawasaki syndr.),   with remainder.inj.IM into glut.reg. In cases of sev.les./ proximity to   inactiv.influenza vacc.using separ.syringe.
       erythema multiforme.          CNS/late consultat/pt.immunodefic.2 x0,5 ml dos.on Day 0 poss.justif.
       Warnings and special precautions: Avoid pregn. for 1 mnth.   In cases of sev. bites admin 20 iu/kg bm of specif.human rabies im-
       post immunisat., postpone admin. in ac.sev.febrile illn., ensure pro-  mune globul.in conjunct.with 1st dos.to provide immed. protect.anti-
       ced.in place to avoid injury from faint.as syncope.poss., disinfect.  bod. Vaccinat.of pre-immunis. indiv: If less than 5 yrs.aft.last.vac-  27  ENZYMES
       agents on skin poss.inactiv.virus if not evaporat.bef.admin., limit.  cinat. dos: 2 booster inj.of 0,5 ml on days D0 & D3. Pts vaccinat. more
       varicella protect.obt. with vaccinat.within 72 hrs.of natur.expos., a   than 5 yrs.prev./vaccinat. incomplete to be treat.as unvaccinat.subj.     (See also 8.3, 12.1, 26)
       protect.immune respon.may not be elicit.in all vaccinees, mild vari-  Contraindications: Pre-expos: Postpone in event of fev./ac.illn./
       cella dis.poss.in persons who prev.receiv. Varilrix., avoid cont.with   chron.evolut.dis., assess benef. vs.risk bef.admin.dur.pregn. Post   ACTILYSE, Boehringer Ingelheim (Pty) Ltd
       immune-comprom. pts.due to HIV/other immunodefic.for 14 days   expos: No contra-indicat.as rabies infect.gen.results in death., in-  See Section 8.3
       post immunisat., immunocompromis.pts., in ac.phase of leukaem.  travasc.admin., combin.with human rabies immunoglobul.& vacc.in
       withold maint.chemother.1 wk. bef & 1 wk.aft.immunisat.& do not   same syringe/inj.at same site.  ALDURAZYME, Sanofi-Aventis [P/S]
       immunise pts.undergo.radiother.dur.treatm.phase, dissemin. vari-  Side effects: Loc.reacts., slight indurat. System. reacts.report.but   Laronidase
       cella with intern.organ involvem., other live attenuat.vacc. admin.  causal.relationship not est incl mod.fev., shiver., malaise, asthen.,   Indications: Long-term enz.replacem.ther.in pts. with confirm.
       at same time in high-risk pts , appropr.medic.treatm.to be avail.in   headaches, dizzin., arthralg., myalg., GI disturbs., allerg.skin reacts.,   diagnos.of mucopolysaccharidos.to treat non-neurologic.mani-
       case of anaphylax., monit.x 30 mins.for poss. anaphylax., lact in-  anaphylact.react.  festat.of dis.
       tol., do not mix.with other vacc. in same syr., perf.tuberculin test   Special precautions: 6 mnth.serologic.test recomm. in indiv.at incr./  (S4) CONC.FOR SOL.FOR INFUS, 44/31/0500
       bef./simultan. with vaccinat., avoid tuberculin test.for 4-6 wks. aft.   contin.expos.risk, serologic. test recomm.every 2-3 yrs.aft.booster at   714056-001: 500 U(2,9 mg)/5 ml 1x5 ml, R8 855,41
       vaccinat., lactat.,delay immunisat.x3mnths.in pts. who have receiv.  1 yr.& 5 yrs where expos.risk.freq., in immunodefic. indiv.serologic.  Dosage: Admin.by exper.practit.in an appropr. clinic. sett.with
       immune globul./bld.transfus., other vaccinat.poss.at diff.sites at the   test.2-4 wks.aft. vaccinat.admin.boost./addit.inj.if antibody titre   resus.equipm.
       same time, observ.1 mnth.interv.aft.measle vaccinat, avoid salicy-  &lt;0,5 IU/ml, neomycin hypersens., adhere strict.to method of admin.  Recomm.dos: 100 U (0.58 mg)/kg bw once wkly. as IV infus.over
       lates for 6 wks aft.vaccinat.as Reye’s syndr. poss.  as fatalat.report.when not follow.  3-4 hrs. Init.infus.rate 2 U/kg/hr; may incr rate incremental.every 15
       Interactions: Live vir. vaccinat.may depress. tubercul.skin sensitiv.  Drug interactions: Corticoster.& immunosuppress. ther.may lead   min as tol.to max 43 U/kg/hr
                                                                  Side effects: Infus.-assoc.reacts., anaphylact. react., angioed,
       VAXIGRIP, Sanofi Aventis [P/S]  to vaccinat.fail.          psych./CNS disords., tachycard., flush., hypotens., pallor, periph.
       Flu vaccine. Formulat.varies each year accord.to WHO recom-  VIVAXIM, Sanofi-Aventis [P/S]  coldness./oed., resp. distress, bronchosp., dyspn., cough, GI
       mendat.                       Purif.Salmonella typhi Vi capsul.polysaccharide (Ty 2 strain) 0,025 mg,   disords., rash, swell.of face, urticar., prurit., cold sweat, alopec.,
       Indications: Flu prophylax.   Hepatit. A virus GBM strain (inactivat.) 160 U/1 ml  hyperhidros., arthropathy, arthralg., back/extremity/musculoskelet.
       (S2) INJ. T/30.1/674.                                      pain, pyrex., infus.site reacts., chills, feeling hot/cold, fatig.,
       836591-003: 1x paed.prefill.syr.0,25 ml, R54,54            influenza-like illn., incr.body temp., oxygen saturat. decr./hypoxia,
       813338-018: 1x sngl.dos.prefill.syr.0,5 ml, R65,76         erythema, tachypn, extravasat., IgG antibod.developm
       813338-019: 10x sngl.dos.prefill.syr.0,5 ml, R657,60       Warnings and special precautions: Infus. assoc. reacts.(IARs),
       Dosage: IM/deep SC admin.                                  monit.antibody status reg., monit.pts.with pre-exist.sev.underly.
       Adults.& childr.over 36 mnths: 0,5 ml. Childr.6-35 mnths:   upper airway involvem. & only infus.in appropr.clinic.sett.with
                                 nd
       0,25 ml. Childr.und.8 yrs. not prev. vaccinat.should receiv.2  dos.  Dosages given   resuscitat.equipm., pts with ac.underly.illn.at time of infus.poss.
       aft.an interv.of at least 4 wks.                           at great.IAR risk, pts.who have develop. antibod./sympts.of IARs,
       Contraindications: Ac.fev., egg/chicken prot./ neomycin allerg.,   are for adults only   incr.risk of hypersens. react.after prolong.treatm.interrupt., admin.
       IV admin., childr.und.6 mnths.                             antipyrets.&/antihistamin.60 mins.prior to infus., discont.immed.if
       Side effects: Loc./syst./allerg.reacts., gen.skin reacts., anaphylax.,   unless otherwise   sev.allerg./anaphylact.-type reacts.occ.& init.approp.treatm, pts.on
       neuralg., parasthes., vasculit., convuls., trans. thrombocytopen.,   stated.  control. Na diet, safety & effic.not eval.in ren./ hepat.insuffic/pts.&gt;
       neurit., encephalomyelit., Guillain Barre syndr.           65 yrs., pregn.& lactat.
       Special precautions: Immunosuppress., pts. show. allerg./ab-  Interactions: Chloroquine/procaine poss.interf. with intracellul.
       norm.reacts.to prev.vaccin., febr. react. poss.precipit.an attack in   uptake of laronidase
       sickle cell dis., pregn.
       Drug interactions: Dimish.immunolog.respon.in pts. on immu-  ELAPRASE, Sanofi-Aventis [P/S]
       nosuppress.treatm.                                         Idursulfase</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page377.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page373.html">373</a>&nbsp;&nbsp;&nbsp;<a href="page374.html">374</a>&nbsp;&nbsp;&nbsp;<a href="page375.html">375</a>&nbsp;&nbsp;&nbsp;<a href="page376.html">376</a>&nbsp;&nbsp;&nbsp;<a href="page377.html">377</a>&nbsp;&nbsp;&nbsp;<a href="page378.html">378</a>&nbsp;&nbsp;&nbsp;<a href="page379.html">379</a>&nbsp;&nbsp;&nbsp;<a href="page380.html">380</a>&nbsp;&nbsp;&nbsp;<a href="page381.html">381</a>&nbsp;&nbsp;&nbsp;<a href="page382.html">382</a>&nbsp;&nbsp;&nbsp;<a href="page383.html">383</a>
             </td>
             <td width="35%"><a href="page379.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page379.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
